Caprolactam Chemicals Ltd

For the fourth consecutive session, Caprolactam Chemicals Ltd has seen its share price decline, culminating in a fresh 52-week low of Rs 37.1 on 20 Aug 2026. This marks an 18.37% drop over the last four days, underscoring persistent selling pressure despite a broadly positive market backdrop.

Caprolactam Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from an attractive to a very attractive price range, as reflected in its latest price-to-earnings (P/E) and price-to-book value (P/BV) ratios. Despite a recent decline in share price, the company’s valuation metrics now position it favourably against peers and historical averages, prompting a reassessment of its investment appeal amid a challenging commodity chemicals sector backdrop.

Caprolactam Chemicals Ltd has reported a significant deterioration in its financial performance for the quarter ended June 2026, reversing a previously positive trend. The company’s profitability metrics have contracted sharply, with key indicators such as PAT, PBDIT, and EPS showing marked declines compared to both the previous quarter and historical averages. This downturn has led to a downgrade in its Mojo Grade to Strong Sell, reflecting heightened investor caution amid challenging market conditions.

Caprolactam Chemicals Ltd, a micro-cap player in the commodity chemicals sector, has seen its investment rating downgraded from Hold to Sell as of 27 July 2026. This shift reflects a deterioration in technical indicators alongside mixed financial performance and valuation concerns, prompting a reassessment of the stock’s attractiveness for investors.

Caprolactam Chemicals Ltd has seen its investment rating upgraded from Sell to Hold, reflecting a notable improvement in its technical indicators and robust quarterly financial results. The upgrade, effective from 22 July 2026, is driven by a combination of enhanced technical trends, strong financial growth, attractive valuation metrics, and a stabilising quality outlook amid a challenging commodity chemicals sector.

Caprolactam Chemicals Ltd., a micro-cap commodity chemicals manufacturer with a market capitalisation of ₹22.00 crores, reported a remarkable turnaround in Q4 FY26 (January-March 2026), posting net profit of ₹0.84 crores compared to a loss of ₹0.45 crores in the same quarter last year. The stock has responded positively to the operational recovery, gaining 18.60% over the past year, though it remains 39.46% below its 52-week high of ₹81.00. At the current market price of ₹49.04, the company trades at a concerning valuation of 2,254 times trailing twelve-month earnings, raising serious questions about sustainability despite improved fundamentals.

Caprolactam Chemicals Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 27 May 2026, driven primarily by deteriorating technical indicators and stagnant financial performance. Despite a modest one-year stock return outperforming the broader market, the company’s weak fundamentals and bearish technical trends have raised concerns among analysts and investors alike.

Caprolactam Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 Oct 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 15 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Caprolactam Chemicals Ltd, a micro-cap player in the commodity chemicals sector, has witnessed a significant shift in its valuation parameters, raising questions about its price attractiveness amid a volatile market backdrop. The company’s price-to-earnings (P/E) ratio has surged to an extraordinary 2,688.7, while its price-to-book value (P/BV) stands at 5.05, marking a transition from fair to expensive valuation territory. This article analyses these valuation changes in the context of historical trends, peer comparisons, and broader market performance to provide investors with a comprehensive perspective.

Caprolactam Chemicals Ltd has experienced a notable shift in its valuation parameters, moving from an attractive to a fair rating despite its sky-high price-to-earnings (P/E) ratio. This transition reflects a complex interplay of market sentiment, financial metrics, and sector comparisons, raising important considerations for investors navigating the commodity chemicals space.

Caprolactam Chemicals Ltd, a micro-cap player in the commodity chemicals sector, has witnessed a notable shift in its valuation parameters, moving from a previously fair to an attractive valuation grade. Despite a challenging market environment reflected in its recent share price decline, the company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a potential re-rating opportunity relative to its historical and peer benchmarks.

Caprolactam Chemicals Ltd has witnessed a notable shift in its valuation parameters, moving from an expensive to a fair valuation grade despite a significant decline in its share price. This change reflects evolving market perceptions amid mixed financial metrics and peer comparisons within the commodity chemicals sector.

Caprolactam Chemicals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 27 October 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 05 February 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Caprolactam Chemicals Ltd has surged to a fresh 52-week high of Rs.81, marking a significant milestone in its stock performance. This new peak reflects strong momentum as the stock continues its upward trajectory, outperforming its sector and broader market indices.

Caprolactam Chemicals Ltd has surged to a fresh 52-week high of Rs.77.7, marking a significant milestone in its stock performance. This new peak reflects strong momentum in the commodity chemicals sector, with the stock outperforming its peers and broader market indices over recent sessions.